Facet Biotech Corporation
1400 Seaport Boulevard
Redwood City,
CA 94063
United States - Map
Phone: 650-454-1000
Web Site: http://www.facetbiotech.com
| Facet Biotech Corporation, a biotechnology company, engages in the identification and development of oncology therapeutics. Its products in development include Daclizumab, a monoclonal antibody in Phase II clinical studies that binds to the alpha chain of the interleukin-2 receptor on activated T cells; and Volociximab, which is in Phase I/II clinical studies is a chimeric monoclonal antibody that inhibits the functional activity of a protein in activated endothelial cells. The company is also developing Elotuzumab, a monoclonal antibody in Phase I clinical study, which binds to a cell surface glycoprotein that is expressed on myeloma cells and normal human cells; PDL192, a monoclonal antibody in Phase I clinical study, which binds to the tumor necrosis factor-like weak inducer of apoptosis receptor; and PDL241, a monoclonal antibody in the preclinical stage for immunologic diseases. Facet Biotech Corporation has a collaboration agreement with Biogen Idec Inc. The company is headquartered in Redwood City, California. Facet Biotech Corporation operates independently of PDL BioPharma Inc. as of December 18, 2008. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Faheem Hasnain , 50
Chief Exec. Officer, Pres, Director and Member of Equity Grant Committee |
$
215.00K | N/A | Mr. Andrew L. Guggenhime , 40
Chief Financial Officer and Sr. VP |
$
641.00K | N/A | Dr. Mark McCamish M.D., Ph.D., 56
Chief Medical Officer and Sr. VP |
N/A
| N/A | Dr. Maninder Hora Ph.D., 55
VP of Product & Quality Operations |
$
488.00K | N/A | Mr. Francis Sarena , 38
VP, Sec. and Gen. Counsel |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.34% Nasdaq 
0.06 (0.36%) 
Profile
